Atara Biotherapeutics, Inc. (ATRA)

NASDAQ: ATRA · IEX Real-Time Price · USD
4.72
-0.22 (-4.45%)
At close: Aug 17, 2022 4:00 PM
5.20
+0.48 (10.17%)
After-hours: Aug 17, 2022 6:02 PM EDT
-4.45%
Market Cap 445.39M
Revenue (ttm) 71.81M
Net Income (ttm) -247.65M
Shares Out 94.36M
EPS (ttm) -3.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,404,166
Open 4.86
Previous Close 4.94
Day's Range 4.64 - 5.02
52-Week Range 2.83 - 20.04
Beta 1.08
Analysts Buy
Price Target 20.18 (+327.5%)
Earnings Date Aug 8, 2022

About ATRA

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies a... [Read more...]

Industry Biotechnology
IPO Date Oct 16, 2014
CEO Pascal Touchon
Employees 578
Stock Exchange NASDAQ
Ticker Symbol ATRA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for ATRA stock is "Buy." The 12-month stock price forecast is 20.18, which is an increase of 327.54% from the latest price.

Price Target
$20.18
(327.54% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Does Atara Biotherapeutics (ATRA) Have the Potential to Rally 204% as Wall Street Analysts Expect?

The mean of analysts' price targets for Atara Biotherapeutics (ATRA) points to a 204.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement a...

Atara Biotherapeutics (ATRA) Reports Q2 Loss, Tops Revenue Estimates

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 65.93% and 483.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative ...

ATARA ALERT: Bragar Eagel & Squire, P.C. is Investigating Atara Biotherapeutics, Inc. on Behalf of Atara Stockholders...

NEW YORK--(BUSINESS WIRE)-- #ATRA--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (“Atara” or the...

ATRA INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud ...

NEW YORK , Aug. 4, 2022 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA) concerning pos...

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative ...

Atara Biotherapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to de...

After Plunging 65.7% in 4 Weeks, Here's Why the Trend Might Reverse for Atara Biotherapeutics (ATRA)

Atara Biotherapeutics (ATRA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts i...

Atara Biotherapeutics to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to de...

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Atara Biotherapeutics, Inc. with Losses of $100,000 ...

LOS ANGELES--(BUSINESS WIRE)---- $ATRA #ATRA--The Schall Law Firm Encourages Investors in Atara Biotherapeutics, Inc. with Losses of $100,000 to Contact the Firm

ATRA INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud...

NEW YORK , July 14, 2022 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA) concerning po...

Why Atara Biotherapeutics Stock Is Crashing Today

Investors were hoping for more from the company's latest clinical update.

Mizuho On Atara Biotherapeutics - Distinguish Between Small Numbers And Science Failure

Atara Biotherapeutics Inc (NASDAQ: ATRA) issued its anticipated interim analysis communication for its ATA188 Phase 2 progressive multiple sclerosis trial. Shares slumped over 50%.

Atara Biotherapeutics (ATRA) Moves 17% Higher: Will This Strength Last?

Atara Biotherapeutics (ATRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength ...

Atara Biotherapeutics Shares Are Plummeting - Read Why

Atara Biotherapeutics Inc (NASDAQ: ATRA) completed the planned Interim Analysis of the ATA188 Phase 2 study (EMBOLD) in progressive multiple sclerosis patients. The analysis' primary focus was on expand...

Atara Biotherapeutics Announces Completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progr...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative ...

Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to de...

Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Progra...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative ...

Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics

Late last week, Atara Biotherapeutics Inc (NASDAQ: ATRA) announced that Bayer AG (OTC: BAYRY) intends to terminate the exclusive worldwide licensing agreement for Atara's mesothelin-targeted allogeneic ...

Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative ...

Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 11.22% and 11.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Atara Biotherapeutics Announces First Quarter 2022 Financial Results and Operational Progress

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative ...

Atara Biotherapeutics to Announce First Quarter 2022 Financial Results on Thursday, May 5, 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to de...

Analysts Estimate Atara Biotherapeutics (ATRA) to Report a Decline in Earnings: What to Look Out for

Atara Biotherapeutics (ATRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Atara Biotherapeutics Names Biopharmaceutical Executive Charlene Banard as Chief Technical Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative ...